KalVista Pharmaceuticals Valuation Multiples

KalVista Pharmaceuticals Overview

About KalVista Pharmaceuticals

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Founded

2004

HQ

Employees

270

Website

kalvista.com

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: $94M

Net Income: ($91M)

EV

$901M

Valuation Multiples

Multiples.vc

Start free trial

KalVista Pharmaceuticals Financials

KalVista Pharmaceuticals reported last 12-month revenue of $94M.

In the same LTM period, KalVista Pharmaceuticals generated $86M in gross profit and had net loss of ($91M).

KalVista Pharmaceuticals P&L

In the most recent fiscal year, KalVista Pharmaceuticals reported revenue of $49M and EBITDA of ($173M).

KalVista Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals has current market cap of $1B, and enterprise value of $901M.

KalVista Pharmaceuticals' stock price is $20.49.

KalVista Pharmaceuticals Valuation Multiples

KalVista Pharmaceuticals trades at 9.6x EV/Revenue multiple, and (5.2x) EV/EBITDA.

KalVista Pharmaceuticals Financial Valuation Multiples

As of April 20, 2026, KalVista Pharmaceuticals has market cap of $1B and EV of $901M.

Equity research analysts estimate KalVista Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

KalVista Pharmaceuticals has a P/E ratio of (11.5x).

KalVista Pharmaceuticals Margins & Growth Rates

KalVista Pharmaceuticals' revenue in the last 12 month grew by 150%.

KalVista Pharmaceuticals' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.7M for the same period.

KalVista Pharmaceuticals' rule of 40 is 98% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

KalVista Pharmaceuticals' rule of X is 248% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

KalVista Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

KalVista Pharmaceuticals M&A Activity

KalVista Pharmaceuticals acquired XXX companies to date.

Last acquisition by KalVista Pharmaceuticals was on XXXXXXXX, XXXXX. KalVista Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

KalVista Pharmaceuticals Investment Activity

KalVista Pharmaceuticals invested in XXX companies to date.

KalVista Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. KalVista Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).